Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
Public ClinicalTrials.gov record NCT00853827. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study will assess the change in coronary atherosclerotic disease as determined by intravascular ultrasound (IVUS) for aliskiren compared to placebo when given in addition to standard therapy in patients with coronary artery disease (CAD) and a blood pressure in the pre-hypertensive range.
Study identification
- NCT ID
- NCT00853827
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 613 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 35 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2009 (Type not available)
- Primary completion
- Jan 2013 (Actual)
- Completion
- Jan 2013 (Actual)
- Last update posted
- Jun 3, 2014
2009 – 2013
United States locations
- U.S. sites
- 54
- U.S. states
- 27
- U.S. cities
- 51
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Mobile | Alabama | 36693 | — |
| Novartis Investigative Site | Phoenix | Arizona | 85054 | — |
| Novartis Investigative Site | Tucson | Arizona | 85723-0001 | — |
| Novartis Investigative Site | Tucson | Arizona | 85745 | — |
| Novartis Investigative Site | Los Angeles | California | 90033 | — |
| Novartis Investigative Site | Los Angeles | California | 90095 | — |
| Novartis Investigative Site | San Diego | California | 92161 | — |
| Novartis Investigative Site | Stockton | California | 95204 | — |
| Novartis Investigative Site | Torrance | California | 90502 | — |
| Novartis Investigative Site | Boulder | Colorado | 80304 | — |
| Novartis Investigative Site | Farmington | Connecticut | 06030-3100 | — |
| Novartis Investigative Site | Washington D.C. | District of Columbia | 20010 | — |
| Novartis Investigative Site | Washington D.C. | District of Columbia | 20037 | — |
| Novartis Investigative Site | Gainesville | Florida | 32610 | — |
| Novartis Investigative Site | Hudson | Florida | 34667 | — |
| Novartis Investigative Site | Miami | Florida | 33137-3732 | — |
| Novartis Investigative Site | Port Charlotte | Florida | 33952 | — |
| Novartis Investigative Site | Safety Harbor | Florida | 34695 | — |
| Novartis Investigative Site | Decatur | Georgia | 30033 | — |
| Novartis Investigative Site | Elkhart | Indiana | 46514 | — |
| Novartis Investigative Site | Lexington | Kentucky | 40536 | — |
| Novartis Investigative Site | Louisville | Kentucky | 40202 | — |
| Novartis Investigative Site | Covington | Louisiana | 70433 | — |
| Novartis Investigative Site | Columbia | Maryland | 21044 | — |
| Novartis Investigative Site | Boston | Massachusetts | — | — |
| Novartis Investigative Site | Flint | Michigan | 48532 | — |
| Novartis Investigative Site | Kalamazoo | Michigan | 49048 | — |
| Novartis Investigative Site | Midland | Michigan | 48640 | — |
| Novartis Investigative Site | Petoskey | Michigan | 49770 | — |
| Novartis Investigative Site | Saginaw | Michigan | 48601 | — |
| Novartis Investigative Site | Rochester | Minnesota | 55905-0001 | — |
| Novartis Investigative Site | Saint Paul | Minnesota | 55102 | — |
| Novartis Investigative Site | Columbia | Missouri | 65212 | — |
| Novartis Investigative Site | Ridgewood | New Jersey | 07450 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87131-5271 | — |
| Novartis Investigative Site | Buffalo | New York | 14215 | — |
| Novartis Investigative Site | New York | New York | 10011 | — |
| Novartis Investigative Site | Syracuse | New York | 13210-1640 | — |
| Novartis Investigative Site | Williamsville | New York | 14221 | — |
| Novartis Investigative Site | Raleigh | North Carolina | 27610 | — |
| Novartis Investigative Site | Fargo | North Dakota | 58122 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44109-1998 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73109 | — |
| Novartis Investigative Site | Tulsa | Oklahoma | 74104-4243 | — |
| Novartis Investigative Site | Bend | Oregon | 97701 | — |
| Novartis Investigative Site | Hillsboro | Oregon | 97123 | — |
| Novartis Investigative Site | Danville | Pennsylvania | 17822-2001 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15213 | — |
| Novartis Investigative Site | Johnson City | Tennessee | 37604 | — |
| Novartis Investigative Site | Memphis | Tennessee | 38104 | — |
| Novartis Investigative Site | Oak Ridge | Tennessee | 37830 | — |
| Novartis Investigative Site | Dallas | Texas | 75226 | — |
| Novartis Investigative Site | Katy | Texas | 77493 | — |
| Novartis Investigative Site | San Antonio | Texas | 78229-3900 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 75 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00853827, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2014 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00853827 live on ClinicalTrials.gov.